Table 1.
Pre-clinical studies for co-delivery of miRs and chemotherapeutics in cancer.
| MiR Therapeutic | Chemotherapeutic | Delivery Vehicle | Cancer Type | Ref. |
|---|---|---|---|---|
| miR-7 | Paclitaxel | PEG-PLGA-poly(l-lysine) nanoparticles | Ovarian cancer | [181] |
| miR-10 inhibitor | Paclitaxel | pH-sensitive liposomes | Breast cancer | [182] |
| miR-21 inhibitor | Doxorubicin | Core-shell tecto dendrimers | Breast cancer | [166] |
| NIR-responsive hollow gold nanoparticles | Breast cancer | [172] | ||
| Amphiphilic copolymers | Glioma | [169] | ||
| Graphene oxide-based nanoparticles | Breast cancer | [168] | ||
| Epirubicin | MUC1 aptamer-targeted poymers | Breast cancer | [167] | |
| Docetaxel | Chitosome | TNBC | [164] | |
| Cisplatin | Nano-Graphene oxide nanoparticles | Lung cancer | [183] | |
| 5-FU | Engineered exosomes | Colon cancer | [161] | |
| 5-FU | Poly(amidoamine) dendrimers | Human glioma | [163] | |
| Gemcitabine | Dendrimer-entrapped gold particles using UTMD | Pancreatic cancer | [184] | |
| PEG-PEI magnetic iron oxide nanoparticles | Pancreatic cancer | [165] | ||
| Pemetrexed | Lipid-polymer hybrid nanoplexes | Glioblastoma | [185] | |
| Cationic lipid nanoparticles | Glioblastoma | [170] | ||
| Sorafenib | Dual targeting reconstituted HDL | Hepatocellular carcinoma | [186] | |
| 4-Hydroxy-tamoxifen | PLGA-b-PEG nanoparticles | Breast cancer | [187] | |
| miR-29b | Retinoic acid | Micellar nano system | NSCLC | [188] |
| miR-31 | Doxorubicin | Stimuli-responsive silica nanoparticles | HeLa cell line/tumors | [189] |
| miR-34a | Doxorubicin | Hyaluronic acid chitosan nanoparticles | TNBC | [177] |
| Cationic polypeptide-based micelles | Prostate cancer | [176] | ||
| Paclitaxel | Lipid nanoparticles | Melanoma lung metastases | [174] | |
| Irinotecan | Polymeric hybrid micelles | Colorectal cancer | [173] | |
| Notch1 antibody | PLGA nanoparticles | TNBC | [180] | |
| tRNA-mir-34a | Doxorubicin | Creatin-based polymer | Breast cancer lung metastases | [190] |
| miR-34a activator rubone | Docetaxel | Dual responsive micelles | Prostate cancer | [191] |
| miR-122 | Doxorubicin | Gold nanocages | Hepatocellular carcinoma | [192] |
| 5-FU | Chitosan nanoparticles | Hepatocellular carcinoma | [193] | |
| miR-181a | Melphalan | Lipid nanoparticles | Retinoblastoma | [194] |
| miR-200 | Irinotecan | pH-sensitive and peptide-modified liposomes and solid lipid nanoparticles | Colorectal cancer | [195] |
| miR-200c | Docetaxel | Gelatinases-responsive nanoparticles | Gastric cancer | [196] |
| miR-205 | Gemcitabine | Cationic copolymers | Pancreatic cancer | [197] |
| miR-218 | Temozolomide | Folate-chitosan gel-delivered gold nanoparticles | Glioblastoma & lung cancer | [198] |
| miR-221/222 inhibitors | Paclitaxel | Calcium phosphate-polymer hybrid nanoparticles | TNBC | [199] |
| miR-345 | Gemcitabine | Polymeric dual delivery nanoscale device | Pancreatic cancer | [200] |
| miR-375 | Cisplatin | Lipid-coated nanoparticles | Hepatocellular carcinoma | [201] |
| miR-451 | Doxorubicin | Coated calcium carbonate nanoparticles | Multidrug resistant bladder cancer | [202] |
| miR-542-3p mimic | Doxycycline | HA/PEI-PLGA nanoparticles | TNBC | [203] |
| miR-1284 | Cisplatin | CD59 receptor-targeted liposomes | Cervical cancer | [204] |